HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Get CME credit for this article Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Tokuda, Y. Articles by Miyagi, S. Search for Related Content PubMed PubMed Citation Articles by Tokuda, Y. Articles by Miyagi, S.

Intrapleural Fibrinolytic Agents for Empyema and Complicated Parapneumonic Effusions^*

A Meta-analysis

^* From the Department of Medicine (Dr. Tokuda), Okinawa Chubu Hospital, Okinawa, Japan; the Department of Family Medicine (Dr. Matsushima), Jichi Medical School, Tochigi, Japan; the Department of Medicine (Dr. Stein), College of Medicine, University of Florida, Gainesville, FL; and Muribushi Project for Okinawa Residency Program (Dr. Miygi), Okinawa, Japan.

Correspondence to: Yasuharu Tokuda, MD, 203 Park Dr #246, Boston, MA 02215; e-mail: tokuyasu{at}orange.ocn.ne.jp

Abstract

Background: Randomized controlled trials have shown conflicting findings about the role of intrapleural fibrinolytic therapy for the treatment of empyema and complicated parapneumonic effusions in adult patients.

Objectives: To assess the clinical efficacy and summarize the current evidence of intrapleural fibrinolytic use in patients with empyema and complicated parapneumonic effusions in adult patients.

Methods: We performed a meta-analysis of all properly randomized trials comparing intrapleural fibrinolytic agents with placebo in adult patients with empyema and complicated parapneumonic effusions. Outcome of primary interest was the reduction of death and surgical intervention.

Results: We included five trials totaling 575 patients. The number of enrolled patients for each trial was small, except for the recent trial by Multicenter Intrapleural Sepsis Trial (MIST1) group. Compared with placebo, intrapleural fibrinolytic therapy was associated with a nonsignificant reduction in death and need for surgery (27.6% of the treatment group vs 32.8% of the control group; random-effects pooled risk ratio, 0.55; 95% confidence interval, 0.28 to 1.07; heterogeneity, p = 0.023). A separate analysis for outcomes on either death or need for surgery also showed nonsignificant results.

Conclusion: Our meta-analysis does not support the routine use of fibrinolytic therapy for all patients who require chest tube drainage for empyema or complicated parapneumonic effusions. However, there was significant heterogeneity of the treatment effects among the trials. Selected patients might benefit from the treatment.

Key Words: empyema • fibrinolysis • pleural effusion

This article has been cited by other articles:

				M. Menendez-Gonzalez, P. Oliva-Nacarino, and A. Alvarez-Cofino Cerebral Gas Embolism Caused by Pleural Fibrinolytic Treatment Stroke, September 1, 2007; 38(9): 2602 - 2604. [Abstract] [Full Text] [PDF]

				P. Mattei and J. L. Allen Treatment of Empyema in Children: From Hippocrates' Time to the Present, and Back Again Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 110 - 111. [Full Text] [PDF]